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OBJECTIVES The goal of this study was to identify the factors responsible for embolic complications of
direct current (DC) cardioversion of atrial arrhythmias.
BACKGROUND Direct current cardioversion of atrial fibrillation (AF) carries a risk of thromboembolism,
which is reduced, but not eliminated, by anticoagulation. The risk of embolism after
conversion of atrial flutter is believed to be lower. No series to date has included enough
patients receiving anticoagulants or enough patients with atrial flutter to estimate the risk in
these groups.
METHODS We reviewed the case records of 1,950 patients who underwent 2,639 attempts at DC
cardioversion.
RESULTS Cardioversion was performed within two days of the apparent onset of the arrhythmia in 443
episodes, 352 without subsequent prolonged anticoagulation with one embolic complication.
Cardioversion was preceded by warfarin therapy for3 weeks in 1,932 instances. No embolic
complication occurred in 779 attempts performed with an international normalized ratio
(INR) of 2.5 (95% confidence limits 0% to 0.48%). Of 756 cases in which the INR was
2.5 or was not measured before conversion, nine were complicated by thromboembolism.
Embolism was significantly more common at an INR of 1.5 to 2.4 than at an INR 2.5
(0.93% vs. 0%, p  0.012). The incidence of embolism after conversion of atrial flutter or
tachycardia was similar to that after cardioversion of AF (0.72% vs. 0.46%, p  NS).
CONCLUSIONS The INR should be 2.5 at the time of cardioversion if the duration of AF is uncertain or
2 days. Cardioversion of atrial flutter presents similar risks and requires similar
anticoagulation. (J Am Coll Cardiol 2002;40:926–33) © 2002 by the American College of
Cardiology Foundation
Pharmacologic or electrical conversion of atrial fibrillation
(AF) to sinus rhythm is followed by thromboembolism in
1% to 5% of cases in patients not receiving anticoagulant
therapy (1–8). In a nonrandomized retrospective series of
572 attempted direct current (DC) cardioversions, Bjerke-
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lund and Orning (8) showed that anticoagulation reduced
the frequency of thromboembolic complications from 4% to
0.67% of cardioversion attempts. Subsequent series have
confirmed the safety of the procedure when anticoagulation
is used (9–11). This has led to some complacency with
regard to the control of anticoagulation at the time of
cardioversion, though it is recognized that the risk of
stroke is not eliminated (12). Most authorities currently
recommend that the international normalized ratio
(INR) be maintained between 2 to 3 at the time of
cardioversion (13,14), based on the assumption that the
risk-benefit relation is the same as that in chronic AF
(15,16).
Until recently atrial flutter was often cardioverted without
anticoagulation. This practice was supported by the results
of a single series in which no complication was recorded
after conversion of atrial flutter without anticoagulation in
90 cases (11). In more recent series, patients experienced
cerebral emboli in chronic atrial flutter or after cardioversion
of atrial flutter (17–20). Because atrial flutter is less common
and because most early studies of DC cardioversion made
no distinction between fibrillation and flutter, the available
data are insufficient to estimate the risks of thromboembo-
lism after conversion of atrial flutter. There is no substantial
series of DC cardioversions for other forms of atrial or
junctional tachycardia.
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METHODS
In 13 hospitals in three European countries, we used the
hospital computer system, ward admission records, or an
existing database to identify all patients who underwent DC
cardioversion of atrial arrhythmias between January 1, 1990
and June 30, 1997. We retrieved and reviewed in detail the
hospital notes of 87.2% of patients thus identified. In each
case we determined the rhythm present immediately before
each cardioversion, the apparent duration of that arrhyth-
mia, the duration of anticoagulant therapy, the INR on the
day of cardioversion, the energy of each shock administered,
the duration of sinus rhythm after cardioversion, and the
occurrence of complications within four weeks after cardio-
version. If the case notes contained no record of a clinical
assessment by a physician at four weeks or more after the
cardioversion, we wrote to the physician in charge of the
continuing care of that patient for information on outcome
and complications. We collected details of the clinical
course to at least four weeks for 90% and to at least three
weeks for 97% of those whose case notes we reviewed.
Definitions. The rhythm for which cardioversion was per-
formed was determined by review of the case notes and the
precardioversion electrocardiogram. The duration of that
arrhythmia was determined from the history recorded in the
case notes. Patients were classified as having had a “definite”
embolic event only if a stroke was documented clinically and
shown by computerized tomography or magnetic resonance
imaging to have been due to a cerebral infarction or if limb
embolism was confirmed by angiography. “Probable” em-
bolic complications included neurologic deficits reported by
a physician but not confirmed by imaging or limb embolism
suspected clinically but not tested by angiography. Con-
firmed myocardial infarction or pulmonary embolism was
classified as a probable, rather than a definite, embolic
complication because either of these events could represent
a cause of AF or a consequence of cardioversion-related
thromboembolism.
Any other condition that caused the patient to consult a
physician within four weeks of cardioversion and any death
in this period was recorded. Death was defined as “expected”
if the patient was dependent on ventilatory or inotropic
support at the time of cardioversion or if death was due to
the progression of a neoplasm or infection present before
cardioversion. Other deaths were described as “unexpected.”
Bleeding was defined as “serious” if transfusion was required
or if the hemorrhage was intracranial.
Anticoagulation practices. In all centers there was a policy
of using anticoagulants for at least three weeks before
cardioversion of AF if the arrhythmia was thought to be of
7 days duration. In cases of AF lasting 24 h, conversion
was usually not followed by prolonged anticoagulation. For
AF of one to seven days’ duration, policies varied. Control
of anticoagulation before cardioversion varied between cen-
ters and evolved over the period of the study. In most of the
hospitals in the study, control has become more strict over
the past seven years, with a trend toward using anticoagu-
lants in AF of shorter duration and an increased frequency
of cancellation because of low INR values. In some cases
flutter was treated in the same manner as AF, but in many
cases anticoagulation was not used for atrial flutter, partic-
ularly in the earlier years of the study period.
Statistical analysis. Comparison of proportions was by
chi-square test or Fisher exact test. Calculation of confi-
dence intervals was based on the assumption of a Poisson
distribution.
Analysis of covariance was performed using SAS (SAS
Institute, Cary, North Carolina).
RESULTS
Our search identified 2,754 patients as having had an
attempted DC cardioversion (Fig. 1). We were able to
obtain the hospital records of 2,401 (87.2%), with a retrieval
rate of97% in the largest center. In 451 cases there was no
record of a DC cardioversion having been performed for an
atrial arrhythmia, mostly in cases where conversion of a
ventricular arrhythmia led to inappropriate coding in a
computer database. We collected data pertaining to 2,639
cardioversion attempts in 1,950 patients. In 2,572 cases of
cardioversion, we were able to collect data on the patients’
status at three to four weeks after cardioversion, the usual
time for routine clinic review. Of the remainder we had data
only to the time of hospital discharge 4 h to 8 h after
cardioversion in 59, data to 5.1  3.6 days in eight cases.
Cardioversion was performed via intracardiac electrodes in
63 cases in 35 patients, including 14 using an implanted
atrial defibrillator. Follow-up information to 4 weeks was
available for all of these. In 34 cases transesophageal
echocardiography was used to exclude atrial thrombus.
Anticoagulation was more rigorous in patients with AF
than in those with other arrhythmias. Patients with AF for
2 days had coumadin anticoagulants before and after
cardioversion in 1,551 of 1,682 cardioversions (92%) and an
INR measured before cardioversion in 1,261 (81.3%) of
these, compared with 56.9% and 75%, respectively, for other
rhythms (p  0.001 and p  0.05, chi-square test). Only
21.6% of patients with atrial flutter or tachycardia for 2
days had a documented INR 2.5 at the time of cardio-
version, compared with 38.3% of patients with AF for 2
days (p  0.001, chi-square test). Patients with AF were
cardioverted later than those with other rhythms (Table 1).
Only 13.3% of cases of AF were converted within two days
of the estimated time of onset, compared with 26.5% of
other arrhythmias (p  0.001, chi-square test).
The INR at the time of cardioversion was not related to
Abbreviations and Acronyms
AF  atrial fibrillation
DC  direct current
INR  international normalized ratio
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patient age. The INR was higher in patients with valvular
AF than in others (2.80  0.82 vs. 2.59  0.73, p  0.001,
unpaired t test) and lower in those with lone AF, heart
failure, or ethanol excess (2.53 0.73, 2.51 0.71 and 2.48
 0.85, all p  0.05, unpaired t test) than in the remainder
of the population.
Complications. Confirmed embolic events occurred after
14 cardioversion attempts in 14 patients, five after cardio-
version of atrial flutter or atrial tachycardia, nine after
conversion of AF (Fig. 1). None of those whose complica-
tion followed cardioversion from atrial flutter or atrial
tachycardia had a previous history of AF. In all cases the
Figure 1. Embolic and other complications within 28 days of direct current (DC) cardioversion. A small number of patients with recent-onset atrial
fibrillation were receiving long-term warfarin therapy, most for paroxysmal arrhythmias or because of prosthetic valves. Arrhythmias of unknown duration
were assumed to have a duration of 2 days.
Table 1. Patient Characteristics
Atrial
Fibrillation
Other
Arrhythmias p Value
Number of patients 1,438 512
Age (yrs) 62.9  12.2 64.0  14.5 NS
% Men 68.3 72.0 NS
Duration of arrhythmia (days) 236  565 97  330  0.001
Lone AF/flutter 319 (22.2%) 119 (23.2%) NS
Ischemic heart disease/CABG 289 (20.1%) 119 (23.2%) NS
Hypertension 287 (20.0%) 60 (11.7%)  0.01
Valvular heart disease 222 (15.4%) 67 (13.1%) NS
Heart failure/cardiomyopathy/LV dysfunction 203 (14.1%) 69 (13.5%) NS
Ethanol excess 128 (8.9) 14 (2.7%)  0.001
Respiratory disease 65 (4.5%) 38 (7.4%)  0.05
Congenital heart disease 14 (1%) 32 (6.3%)  0.001
Thyrotoxicosis 32 (2.2%) 1 (0.2%)  0.01
SA node dysfunction 15 (1.0%) 4 (0.8%) NS
Confirmed emboli 7 (0.46%) 7 (0.72%) NS
AF  atrial fibrillation; CABG  coronary artery bypass grafting; LV  left ventricular; SA  sinuatrial.
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complication followed a successful transthoracic cardiover-
sion. None of the patients had been screened by transesoph-
ageal echocardiography. The embolic events occurred be-
tween 6 h and 22 days after cardioversion (median 1.9 days,
mean 5.1 days). In three cases the patient had undergone a
previous DC cardioversion attempt without complication.
Only one confirmed embolism occurred after conversion of
an arrhythmia thought to have been present for 2 days.
Embolic complications occurred in association with long-
term anticoagulation in nine patients, two of whom did not
have an INR recorded at the time of cardioversion. In the
remaining seven, the INR was between 1.4 and 2.2 (Fig. 2).
The risk of embolism was significantly associated with lower
INR at the time of cardioversion with no embolic events
recorded in 779 attempts at cardioversion with an INR
2.5 compared with 7/754 (0.9%) in those with an INR
2.5 and 2/399 (0.5%) in those whose INR was not
recorded (Fig. 3). The upper one-tailed 95% confidence
limit for the incidence of embolism in this group is 0.48%
from the Poisson distribution, significantly lower than the
1% risk that is commonly quoted for cardioversion in
patients on anticoagulants.
Even if a composite end point of serious hemorrhage and
systemic embolism is used, the incidence of complications
was only 0.13% (95% confidence interval, 0.0024% to
0.72%) in those whose INR was 2.5 at the time of
cardioversion. Among those in whom the INR was known
at the time of cardioversion, the INR was significantly lower
in cases where conversion was complicated by embolism.
The INR was 0.77 lower in the embolic group (95%
confidence limits, 0.17 to 1.37) after correction for age and
underlying heart disease in analysis of covariance.
Of the cases of embolic complication in the presence of
anticoagulation, all were associated with anticoagulation for
over three weeks and two for over six months. All patients
had continued their anticoagulant treatment up to the time
of the complication. The INR at the time of the complica-
tion was known in five cases and ranged from 1.7 to 2.5
(mean  2.1). All of the confirmed emboli occurred in
patients with hypertension or some form of structural heart
disease (Table 2), but this did not constitute a significant
association.
Atrial flutter accounted for an unexpectedly high propor-
tion of the embolic events with an overall rate similar to that
for AF (Table 2). The five embolic events included three
cases associated with warfarin use, one of which did not
have an INR recorded before cardioversion. The others had
an INR of 1.5 and 2.2, respectively (Fig. 2). The overall rate
of embolism in those with atrial flutter receiving anticoagu-
lants (3/323, 0.9%) was similar to that in patients not
receiving anticoagulants (2/376, 0.5%). In the small propor-
tion with an INR 2.5 at the time of cardioversion, there
were no embolic complications (0/122, 0%), but the differ-
ence was not statistically significant.
Figure 2. Shows the international normalized ratio (INR) on the day of cardioversion in 1,533 cases in which cardioversion was preceded by warfarin
therapy, and the INR was checked on the day of cardioversion or on the preceding day. The majority of values 1.5 relate to cardioversion via intracardiac
electrodes.
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Events defined as probable embolic complications oc-
curred in seven cases in addition to the cases of confirmed
embolism. Of these, three occurred in association with
long-term anticoagulation. These events were transient
focal neurologic deficits in four patients, pulmonary embo-
lism diagnosed at postmortem, Q-wave myocardial infarc-
tion, and transient lower limb ischemia each in one patient.
The INR at the time of conversion was not recorded in one
of these patients who were anticoagulated at the time of
cardioversion of AF. It was 1.7 and 2, respectively, in the
others, both of whom had atrial flutter. The median time
between cardioversion and a probable embolic event was 0.8
days.
Chest pain or dyspnea not attributable to pulmonary
edema led to readmission to hospital or attendance at an
emergency room within four weeks after cardioversion in 16
cases (Fig. 1). A pulmonary perfusion scan was performed in
one case and was negative. In all other cases, the patient was
discharged after exclusion of acute myocardial infarction.
The median interval between cardioversion and the onset of
Figure 3. Relation between the international normalized ratio (INR) on the day of cardioversion and the risk of thromboembolism. Confidence intervals
were calculated by assuming a Poisson distribution.
Table 2. Characteristics of Patients With and Without Embolic Complications
Confirmed
Emboli
Other DCC
Attempts p Value
Number of DC cardioversion attempts 14 2,625
Age (yrs) 66.7  12.4 62  12.6 NS
% Men 79 69 NS
Duration of arrhythmia (days) 190  472 183  475 NS
Previous CVA/TIA 0 49 (1.9%) NS
Lone AF/flutter 0 600 (22.7%) NS
Ischemic heart disease/CABG 3 (21.4%) 496 (18.8%) NS
Hypertension 4 (28.6%) 465 (17.6%) NS
Valvular heart disease 3 (21.4%) 424 (16.1%) NS
Including prosthetic valves 1 (7.1%) 137 (5.2%)
Ethanol excess 0 220 (8.2%) NS
Heart failure/cardiomyopathy/LV dysfunction 3 (21.4%) 374 (14.2%) NS
Respiratory disease 1 (7.1%) 150 (5.7%) NS
AF atrial fibrillation; CABG coronary artery bypass grafting; CVA cerebrovascular accident; DC direct current; LV
left ventricular; TIA  transient ischemic attack.
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these symptoms was two days. There was an association
with lower INR in the six cases associated with warfarin use
(p  0.05, two-tailed t test).
Two serious hemorrhages occurred within four weeks
after cardioversion. A 64-year-old man with long-standing
hypertension and two previous cerebral infarctions was
found collapsed 14 days after successful cardioversion of AF
(INR  3.4 at the time of conversion). He was found to
have a more severe hemiparesis, and computed tomography
showed an intracerebral hemorrhage at the site of a previ-
ously documented cerebral infarction. He made a partial
recovery with conservative management. A 60-year-old
woman underwent cardioversion with heparin anticoagula-
tion for recent-onset AF and was subsequently started on
warfarin. She developed a large soft-tissue hematoma after
minor trauma 23 days later associated with uncontrolled
anticoagulation (INR  6.5) but made a full recovery after
transfusion and reversal of anticoagulation.
Only two fatalities can be attributed with reasonable
certainty to DC cardioversion. In one, cardioversion of AF
thought to be of short duration was followed by a fatal
cerebral infarction. In the other, a failed attempt at internal
cardioversion was followed by an unexplained out-of-
hospital cardiac arrest 8 h later. This case has previously
been reported (21) and was the only complication related to
an internal cardioversion. The case of fatal pulmonary
embolism may have been triggered by cardioversion. In nine
other cases, death occurred unexpectedly within 28 days
after cardioversion. In two of these, cardioversion without
anticoagulation was followed by death, which was attributed
on clinical grounds to pulmonary embolism, but autopsy
was not performed. In the remaining seven, death was
attributed to the underlying valvular or ischemic heart
disease or to respiratory failure.
DISCUSSION
The relation between the intensity of anticoagulation and
the risk of thromboembolism in chronic AF has been
carefully documented (15). The risk of complications is
substantially lower when the INR is 2 and very low at
2.5. Because the risk of hemorrhage increases sharply
when the INR exceeds 4 to 5, it is recommended that the
INR be maintained between 2 and 3 in chronic AF when
anticoagulation is indicated. In practice, anticoagulation is
usually adjusted to aim for a target INR of 2.5. In the
absence of data specific to the period surrounding cardio-
version, it has been assumed that the optimum intensity of
anticoagulation is the same as in chronic AF. This assump-
tion ignores the documented excess of thromboembolism
within seven days after conversion. In the absence of
anticoagulation, the incidence of systemic thromboembo-
lism is 1% to 4% in this week, similar to the risk in a year of
continuous AF. There is no evidence of any excess of
hemorrhagic risk in this period, nor is there any theoretical
reason to expect such an excess. The balance of these risks
should, therefore, favor an INR higher than that that is
optimal in chronic AF.
The relation between INR and risk of thromboembolism
that we have observed is qualitatively similar to that docu-
mented in chronic AF. As in previous reports, the absolute
risk of an event in the week after cardioversion was higher
than in chronic AF. There was no apparent increase in the
risk of serious hemorrhage after cardioversion. This suggests
that cardioversion should not be attempted if the INR is
near the lower end of the range considered acceptable for
chronic AF. A lower limit of 2.4 to 2.5 seems reasonable on
the basis of our data. The upper limit for the INR target
range cannot be determined from the current set of data.
International normalized ratio readings above 4 have been
shown to increase the risk of hemorrhage (12) and should
prompt a reduction in warfarin dosage, but an INR above
the desired range should not delay cardioversion.
Atrial flutter. Previous reports have suggested that flutter
carries a low risk of thromboembolism. In our series there
was a nonsignificant excess of risk compared with AF. This
probably occurred due to the documented acceptance of
lower intensity anticoagulation for those with atrial flutter
compared with AF. No series yet published has contained
enough cases of atrial flutter to accurately define the risk of
embolism in this group compared with AF, or to determine
whether anticoagulation reduces the risk. Although our
series did not answer either question conclusively, it shows
that the risk of embolism is appreciable in the absence of
adequate anticoagulation. The absence of embolic compli-
cations in the 122 patients with an INR2.5 is encouraging
but not conclusive.
Lone AF. There was a nonsignificant trend toward lower
incidence of complications in patients without structural
heart disease or hypertension. This finding should not be
interpreted as an indication that anticoagulation can safely
be omitted in such cases. Among those with emboli, one
patient classified as having valvular AF had only mild mitral
regurgitation with normal atrial dimensions, and one pa-
tient classed as hypertensive had well-controlled arterial
pressure without ventricular hypertrophy. Our results sug-
gest that those with lone AF represent a relatively low-risk
subgroup in which a lower INR might be safe.
Acute cardioversion. In AF known to be of 2 days
duration, cardioversion has been reported to be safe even
without anticoagulation (22). We were unable to control the
quality of the estimation of arrhythmia duration in our
series, so we cannot quantify this risk with confidence. We
recorded only one complication associated with an arrhyth-
mia duration 2 days. The physician who performed that
cardioversion later speculated that the estimated duration
was incorrect. As the uncertainty was recorded after the
complication and would probably not have emerged had the
stroke not occurred, we have accepted the initial estimate of
AF duration. This highlights the difficulty in pinpointing
the onset of AF from the history alone. If the onset of AF
has been observed on a cardiac monitor or recorded by an
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implanted device, it may be safe to convert within 48 h
without anticoagulation. In clinical practice the time of
onset is seldom known for certain.
Pathophysiology. The mechanism of embolic complica-
tions is uncertain. They were once thought to occur when
renewed atrial contraction displaced thrombi that had
formed during AF. This theory implied that exclusion of
atrial thrombus by transesophageal echocardiography
should allow cardioversion without anticoagulation. Unfor-
tunately, exclusion of thrombus appears to make no impact
on the risk of embolism when anticoagulation is omitted
(23). Restoration of sinus rhythm is followed by a fall in the
velocity of blood flow in the left atrial appendage (24). It is
now generally accepted that this accentuation of atrial stasis
promotes new thrombus formation and embolization (25).
Our data are in keeping with this hypothesis. We do not
have sufficient data on patients screened by transesophageal
echocardiography to comment on this strategy, except to
state that safe cardioversion is achievable without it.
Study limitations. In a retrospective study, it is not possi-
ble to limit and characterize a cohort as accurately as in a
well-executed prospective trial. We are dependent on the
recording of data by the physician who performed the
cardioversion and reviewed the patient at the subsequent
outpatient visit. A prospective design would have allowed
stricter surveillance for minor embolic events. It would have
allowed longer follow-up after cardioversion, though the
three weeks available in the vast majority of our cases should
have disclosed almost all embolic complications (26). A
prospective study would encounter the same difficulty in
pinpointing the duration of the arrhythmia, but assessment
might have been more consistent. These limitations must be
weighed against the advantage that the retrospective design
avoids filtering and yields results that reflect clinical practice
more accurately than those of a prospective study.
Atrial flutter and atrial tachycardias are a heterogeneous
group. Our study population was not large enough to
measure accurately the risk of embolism for each type of
tachycardia or to produce significant subgroups on subdi-
viding atrial flutter cases according to INR or underlying
disease. A larger series of cardioversion attempts in atrial
flutter and other atrial tachycardias would be needed.
Conclusions. Thromboembolic complications of direct
cardioversion are generally related to inadequate intensity of
anticoagulation. The INR at the time of conversion is
important. Anticoagulation is necessary for the conversion
of atrial flutter as it is for AF. The INR should be 2.5 at
the time of cardioversion of any atrial arrhythmia that has
lasted for longer than two days.
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